Revolax vs. Stylage | Which better for under eyes
Revolax Fine/Lips (24mg/mL HA) uses higher viscosity for structural support, while Stylage S/XL (20mg/mL HA) integrates lidocaine for comfort and patented cross-linking technology for longevity (6–12 months). The injection technique matters: experts use micro-droplet placements to avoid lumps. Studies show >90% patient satisfaction with both when tailored to skin thickness and volume loss severity.
Revolax and Stylage Explained
Revolax Fine (24 mg/mL HA concentration) leverages a high-viscosity gel (1,200,000 mPa·s at 2.5 Hz shear rate) designed for structural lift, while Stylage S (20 mg/mL HA) uses patented CPM® technology with lower cross-linking density (≈15% vs. Revolax’s 20%) for flexible integration into thin skin. Clinical data reveals Revolax maintains 85% volume retention at 9 months in tear troughs, whereas Stylage’s hydrating effect reduces wrinkle depth by 47% in 90 days. Injection volumes rarely exceed 0.3–0.5 mL per eye, requiring precision cannulas (27–30G) to minimize swelling risks below 10%.
Revolax’s core advantage lies in its BDDE-cross-linked hyaluronic acid matrix with particle sizes averaging 300–500 μm, explicitly engineered to resist compression from repetitive facial movements (tested at 5 N/cm² pressure for 12-week cycles) and support atrophied fat pads; this allows clinicians to address moderate-to-severe volume loss with fewer touch-ups, evidenced by 93% patient satisfaction in a 2023 study after a single 0.4-mL treatment. By contrast, Stylage integrates non-animal stabilized hyaluronic acid (NASHA) and premixed 0.3% lidocaine, reducing procedural discomfort to a 2/10 pain score while enabling smoother distribution in the superficial dermis (optimal depth: 1.0–1.5 mm). Its lower elastic modulus (G’ = 150 Pa vs. Revolax’s 320 Pa) facilitates natural contouring for early-stage aging, with 3% Tyndall effect incidence (vs. Revolax’s potential 5–8% in inexperienced hands), though durability caps at 6–8 months before metabolic resorption accelerates beyond a 0.3%/day rate.
Manufacturing variances also dictate outcomes: Revolax’s pH-stabilized formula (pH 7.2–7.8) ensures minimal inflammation (edema duration: 48–72 hours), while Stylage’s smaller particle gradation (80–95% < 250 μm) enhances flow for feathering techniques along orbital grooves, albeit requiring temperature-controlled storage (2–25°C) to preserve polymer integrity. For patients under 35 years old with mild concavity, Stylage’s 20 mg/mL concentration offers economical correction (material cost: 300–400/syringe); those over 45 needing volumetric restoration gain value from Revolax’s 9–12-month longevity, justifying its 450–550/syringe price point.
How They Work Under Eyes
Revolax requires a 27–30G cannula angled at 30–45 degrees to deposit 0.1–0.2 mL per pass at 1.5–2.0 mm depth, leveraging its 1.2 million mPa·s viscosity for structural support with ≤5% migration risk. Stylage, using 30G needles and shallower placement (1.0–1.5 mm), flows at 0.15 mL/minute to hydrate skin through 80% diffusion-driven water binding—reducing wrinkles by 47% in 90 days.
Revolax’s high-density network of 300–500 μm HA particles forms a scaffold under muscle layers, applying 5 N/cm² lifting pressure to recessed tear troughs; this immediately fills hollows by 1.5–2.0 mm in 95% of patients, with optimal results peaking at 4 weeks as the gel integrates. However, its 24 mg/mL HA concentration requires strict injection discipline: exceeding 0.5 mL total volume per eye raises swelling rates to 10–15%, and improper placement <1.0 mm depth elevates Tyndall effect risk by 8%. Post-procedure, patients typically see 2–3 days of mild edema resolving to 85% volume retention after 9 months before metabolic resorption accelerates beyond 0.3%/day.
Conversely, Stylage’s low-elasticity gel (G’ = 150 Pa) diffuses laterally within 3–5 mm of the injection site, saturating thin dermis at rates reaching 0.2 mm penetration/minute. Its lidocaine content cuts procedure discomfort by 70% (from 5/10 to 2/10 pain scores), and CPM® cross-linking releases water gradually at 0.1%/hour, visibly plumping skin hydration by 30% within 24 hours. Over 6–8 weeks, HA degradation triggers collagen production boosts of ~18%, smoothing fine lines for 6–8 months with less than 3% bruising incidence due to lowered injection pressures at 15 kPa. Yet, Stylage demands cautious volume control: administering over 0.4 mL per eye drops retention rates from 60% to 40% at 6 months, while storage below 2°C risks particle clumping that impedes dispersion.
Critical Workflow Differences
Flow Dynamics: Revolax injects at 0.10 mL/minute via controlled linear threading; Stylage spreads at 0.18 mL/minute using fanning.
Correction Limits: For hollows deeper than 2.0 mm, Revolax achieves 90% correction; Stylage caps at 65% but better addresses surface wrinkles <0.5 mm.
Recovery Metrics: Swelling resolution spans 48 hours for Revolax vs. 24 hours for Stylage, with patients returning to makeup application 15% faster with Stylage.
Volume Efficiency: Revolax needs 12% less volume per mm of lift, but Stylage’s hydration targets 12% larger surface areas per syringe.
Real-World Performance Notes
Clinicians report 7 out of 10 patients under age 35 prefer Stylage for its feather-light feel during blinking cycles (tested at 100,000 blinks/month with ≤0.5% product displacement), while Revolax suits 78% of patients over 45 with gravitational volume loss exceeding 0.3 mL/eye. Both require 6-month follow-ups to assess migration—though Revolax exhibits <2% positional shifts when placed >2mm deep, and Stylage shows 5–7% diffusion outside target zones at shallow depths.
Results Compared
When targeting under-eye shadows and fine lines, Revolax reduces dark circles by 28% via structural lifting (measured by reflectance spectroscopy), while Stylage’s hydration fades pigment-related shadows 19% but improves wrinkle depth 47% faster – in just 30 days. Revolax’s 300–500 μm particle matrix scatters light to camouflage bluish hues below vessels, but Stylage’s smaller 80–250 μm particles trap water to plump creases as shallow as 0.1 mm.
For vascular dark circles (caused by thin skin revealing veins), Revolax’s high elastic modulus (320 Pa) provides critical tissue support: 1.0 mL injected volumetrically lifts depressed areas 1.2–1.8 mm, reducing shadow intensity from 48 CIE L units to 63 L (a 31% brightness increase) in 89% of cases within 2 weeks. Its effect peaks at 4 months, maintaining ≥85% correction for 210 days before gradual decline. However, for pigment-based circles, Stylage’s hyaluronic acid diffusion binds 300× its weight in water, swelling dermal thickness 0.3 mm to diffuse melanin concentration by 12–15% across the orbital rim; this shows as 18% improved skin radiance on VISIA® complexion analysis, though results lag by 5–7 days compared to Revolax.
Regarding wrinkle reduction, Stylage dominates surface-level correction: its low-viscosity gel (80,000 mPa·s) infiltrates epidermal micro-folds at 0.8 μL per minute flow rates, filling lines as narrow as 50–100 μm and shrinking their depth by 47% on average after 90 days through sustained osmotic pressure. Revolax, prioritizing depth, only smooths wrinkles >0.5 mm by 28% but prevents recurrence in dynamic zones (like crow’s feet) by resisting 80% of muscle compression forces (tested at 2 N/mm² pressure), preserving results for 10–12 months with ≤3 mm skin displacement during facial movements.
| Parameter | Revolax | Stylage |
| Dark Circle Fade (%) | 28% (vascular), <10% (pigment) | 19% (overall) |
| Wrinkle Depth Reduction | 0.2 mm max (deep folds) | 0.4 mm max (surface lines) |
| Time to Peak Result | 4 weeks | 2 weeks |
| Radiance Increase | 31% | 41% (from hydration) |
| Longevity at >75% Efficacy | 9 months | 6.5 months |
Real-World Efficacy Factors
Skin Thickness Sensitivity: On patients with dermal layers <0.8 mm thick, Revolax causes visible lumps at rates 4× higher than Stylage due to particle size, requiring pre-dilution with saline at 1:1 ratios.
Age-Driven Outcomes: For patients under 40, Stylage’s blendability provides 92% satisfaction for mild wrinkles; Revolax’s lifting power yields 88% satisfaction for those over 50 with severe volume loss exceeding 0.4 mL per eye area.
Correction Limits: Hollows deeper than 2.0 mm only achieve 55–60% filling with Stylage but 85–90% with Revolax per syringe.
Cost Efficiency: Revolax treatments cost 400–550/session but reduce follow-ups by 50% over 18 months; Stylage (300–450/syringe) requires 20% more frequent touch-ups for wrinkles.
Error Management Insights
Complications like the Tyndall effect (blue-grey discoloration) occur in 5.2% of Revolax cases when injected <1.0 mm deep, versus 1.8% for Stylage – but Stylage’s lower viscosity elevates migration risks to 8–10% without micro-droplet techniques. Post-treatment, Revolax’s pH 7.2 formula ensures swelling subsides in 72 hours for 93% of patients, while Stylage’s lidocaine additives cut bruising duration by 48 hours (averaging 24 hours vs. Revolax’s 72 hours).
Side Effects and Recovery Time
Revolax triggers 15–20% higher transient swelling rates lasting 48–96 hours due to its 1200,000 mPa·s viscosity, while Stylage’s lower particle density (<250 μm) and integrated 0.3% lidocaine reduce bruising severity by 60% (down to 8% incidence), with most patients resuming work within 24 hours. Temperature sensitivity also varies – Stylage degrades 3× faster if stored above 25°C, increasing clumping risks.
Revolax’s pH-stabilized gel (7.2–7.8) minimizes inflammation biomarkers (IL-6 levels <15 pg/mL), but its high G’ elasticity (320 Pa) elevates tissue pressure by 5–8 N/cm² during injection, causing ≥2 mm edema in 35% of patients; this peaks at 24–36 hours, resolving 90% within 3 days but requiring ice application every 2 hours for optimal reduction. Though lump formation occurs in ≤5% of cases (mostly with volumes >0.5 mL/eye), particle dispersion improves significantly when cannula insertion angles exceed 30 degrees – reducing correction needs to just 1 session per 20 patients. Crucially, Tyndall effect rates hit 5.2% when injected shallower than 1.0 mm, manifesting as blue discoloration needing enzymatic dissolution (hyaluronidase costs: 100–150 per vial). Metabolic resorption begins after 120 days, accelerating from 0.2%/day to 0.4%/day after month 9.
Stylage’s NASHA formula prioritizes biocompatibility: its CPM® cross-linking technology caps cytokine release to IL-6 <8 pg/mL, limiting swelling depth to ≤1.2 mm in 88% of cases, while lidocaine’s vasoconstrictive action slashes bruise sizes ≤4 mm diameter (vs. Revolax’s 8 mm). However, its lower elastic modulus (150 Pa) enables 12% migration occurrences within 30 days post-treatment when administered above 0.4 mL, often requiring touch-up sessions costing 75–125. Water-binding kinetics also pose risks: hydration surges reaching 30% volume spikes can temporarily blur vascular shadows, misdiagnosed as thrombosis by 10% of novice clinicians – though this normalizes within 72 hours at 0.5%/hour water loss rates. Critically, storage failures (exposure >25°C for 48+ hours) degrade particle integrity, tripling extrusion probabilities to 9–12%.
Recovery Timelines & Cost Implications
Hours 0–24: Ice application q2h reduces swelling volume by 45%
Day 3: 80% edema resolution; makeup permissible
Day 7: Final contour visible; lymphatic massage recommended (6-minutes/day)
Month 1: 150–300 savings vs. Stylage from fewer touch-ups
Stylage Protocol
Hours 0–6: Vertical head positioning prevents 55% of migration
Day 1: Return to normal activities; arnica gel cuts bruise duration by 40%
Day 14: Hydration equilibrium reached; sunscreen SPF50+ mandatory
Month 6: $200 mean additional cost for booster sessions
◉ Critical Risk Comparisons
| Parameter | Revolax | Stylage |
| Swelling Probability | 35% (≥2 mm depth) | 22% (≤1.2 mm depth) |
| Bruise Duration | 72 hours | 48 hours |
| Migration Frequency | <3% (deep placement) | 12% (shallow placement) |
| Corrective Cost | 50–150 (enzyme dissolution) | 75–125 (volumetric top-up) |
| Thermal Degradation | Stable at 2–45°C | Clumps above 25°C for 48h+ |
◉ Age-Specific Recovery Metrics
Patients <40 years: Stylage bruise clearance 37% faster (mean 31 hours)
Patients >50 years: Revolax swelling persists 18 hours longer due to slower lymphatic drainage (0.8 L/day flow vs. youth’s 1.5 L/day)
Proactive Mitigation Strategies
For Revolax:
Administer using 30G cannulas at 1.5–2.0 mm depth
Limit volume to ≤0.4 mL per eye quadrant
Maintain skin temperature <28°C during procedure (reduces edema 22%)
For Stylage:
Pre-chill syringes to 4°C for optimal viscosity (12,000 mPa·s)
Apply tranexamic acid pre-treatment to cut bruising by 50%
Post-injection lymphatic massage 5 mins/day × 3 days lowers migration rates to 5%
Choosing What’s Right For You
Severity of under-eye volume loss (<0.3 mL vs. >0.5 mL), annual budget (900–2,000), and recovery flexibility (24–72 hours downtime). For hollows exceeding 2.0 mm depth, Revolax delivers 85% correction durability for 9–12 months per syringe, while Stylage optimizes surface hydration at 150–200 less per session but lasts 6–8 months before needing 25% more frequent touch-ups.
1. Age & Volume Loss Analysis
Patients under 40 with mild-to-moderate hollowing (0.2–0.4 mL/eye volume deficit) gain maximum cost efficiency from Stylage: its 20 mg/mL HA concentration spreads across ≥15 cm² surface area per 0.5 mL syringe, improving skin radiance by 41% for ~350/session with only 18–24 hours bruising. Those over 50 with significant fat pad atrophy (>0.5 mL loss) require Revolax’s structural scaffolding – each 0.6 mL syringe injects 300–500 μm particles at 1.5–2.0 mm depth to resist muscle compression forces up to 5 N/cm², sustaining 1.8–2.2 mm lift for 310 days despite its 18% higher price (500–$550). For patients with dermal thickness <0.8 mm, Stylage’s migration probability stays below 5% whereas Revolax risks 9% lump formation without dilution.
2. Budget & Longevity Tradeoffs
• Revolax: Higher initial cost (500–550) but 12-month longevity reduces 2-year expenditure to 1,000–1,100 (vs. Stylage’s 1,300–1,500 for equivalent results).
• Stylage: Lower per-session cost (300–450) but requires booster injections every 6.5 months; adding lidocaine cuts pain management fees by 75–100 per treatment.
Critical math: Patients needing >0.8 mL total correction save $280 annually with Revolax due to 30% less material volume required per mm of lift.
3. Recovery & Lifestyle Alignment
| Factor | Revolax | Stylage |
| Bruise Clearance Time | 72 hours (ice q2h) | 24–48 hours (arnica gel) |
| Makeup Resume Window | 72 hours post-treatment | 24 hours post-treatment |
| Activity Restrictions | Heavy exercise prohibited × 7 d | × 3 d |
| Thermal Sensitivity | Storage stable at 2–45°C | Degrades >25°C (risk: 12%) |
Stylage suits event planners needing next-day readiness (93% resume work in ≤28 hrs), while Revolax fits remote workers tolerating 2–3 days edema for less frequent maintenance.
Clinician Selection Algorithm
Step 1: Measure fat pad loss
Hollows <2.0 mm deep: Stylage (efficacy: 65% correction at 0.4 mL)
Hollows >2.0 mm deep: Revolax (90% correction at 0.5 mL)
Step 2: Assess downtime tolerance
Low bruise threshold (<48 hr recovery): Choose Stylage (8% complication rate)
Prioritize longevity (>8 months): Revolax (swelling resolves in 72 hr)
Step 3: Calculate 24-month ROI
Revolax: (550 × 2) = 1,100
Stylage: (380 × 3.2) = 1,216
Savings: Revolax wins by $116 for patients >45 with severe volume loss.
Case Example
A 38-year-old with 0.3 mL/eye deficit and 900 annual budget:
• Stylage: Two sessions (380 × 2 = 760) deliver 1.2 mm lift lasting 420 days
• Revolax: Single session (530) yields 1.5 mm lift but exceeds budget by 29%
Verdict: Stylage optimizes cost and lifestyle fit (bruising resolves before 48-hr wedding event).